Literature DB >> 16020259

Retinal toxicity of commercial tissue plasminogen activator is mediated by the induction of nitric oxide in the mouse retinal primary cells.

Hyun-Sub Oh1, Oh W Kwon, In Chung, Sung C Lee, Hyoung J Koh, Sung-Ho Lee, Joon H Lee.   

Abstract

PURPOSE: Tissue plasminogen activator (tPA) is an efficient thrombolytic agent, but the dose-dependent retinal toxicity of intravitreal injection of commercial tPA (containing L-arginine) has been reported. Here, we sought to investigate the mechanism of tPA-induced cell death in mouse retinal cell cultures and the role of nitric oxide (NO).
METHODS: Primary retinal cell cultures were maintained using glial conditioned medium (GCM) solution. Mouse retinal cell death was observed by using Hoechst-propidium iodide staining. Mouse retinal cell death was also measured by lactate dehydrogenase (LDH) assay. The formation of NO was measured using Griess reagent.
RESULTS: tPA-induced cell death was detected in mouse retinal cell cultures by Hoechst-propidium iodide staining or LDH assay. L-arginine seems to be the major factor in retinal toxicity of commercial tPA (containing L-arginine). The formation of NO was markedly increased in mouse retinal cell cultures treated with tPA (containing L-arginine) or L-arginine. NO inhibitor reduced the cell death induced by commercially available tPA or L-arginine.
CONCLUSIONS: This study suggests that l-arginine from commercial tPA (containing L-arginine) induces the majority of cell death in mouse retinal cell cultures and that its cytotoxicity may depend on the induction of NO.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16020259     DOI: 10.1080/02713680590923267

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  6 in total

1.  Reduction of steroid-induced intraocular pressure elevation in sheep by tissue plasminogen activator.

Authors:  Rosana Gerometta; Sandeep Kumar; Shaily Shah; Larry Alvarez; Oscar Candia; John Danias
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-12-03       Impact factor: 4.799

2.  Increased retinal toxicity of intravitreal tissue plasminogen activator in a central retinal vein occlusion model.

Authors:  Takuhiro Yamamoto; Motohiro Kamei; Paradee Kunavisarut; Mihoko Suzuki; Yasuo Tano
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-10-25       Impact factor: 3.117

3.  Minimally invasive surgery plus recombinant tissue-type plasminogen activator for intracerebral hemorrhage evacuation decreases perihematomal edema.

Authors:  W Andrew Mould; J Ricardo Carhuapoma; John Muschelli; Karen Lane; Timothy C Morgan; Nichol A McBee; Amanda J Bistran-Hall; Natalie L Ullman; Paul Vespa; Neil A Martin; Issam Awad; Mario Zuccarello; Daniel F Hanley
Journal:  Stroke       Date:  2013-02-07       Impact factor: 7.914

4.  Retinal safety of intravitreal rtPA in healthy rats and under excitotoxic conditions.

Authors:  Alejandra Daruich; Jérôme Parcq; Kimberley Delaunay; Marie-Christine Naud; Quentin Le Rouzic; Emilie Picard; Patricia Crisanti; Denis Vivien; Marianne Berdugo; Francine Behar-Cohen
Journal:  Mol Vis       Date:  2016-11-10       Impact factor: 2.367

5.  Effect of amiloride to retinal toxicity induced by tissue plasminogen activator.

Authors:  Ungsoo Samuel Kim; Hyun-Sub Oh; Oh Woong Kwon; In Chung; Sung-Ho Lee; Joon Haeng Lee
Journal:  Korean J Ophthalmol       Date:  2012-09-24

6.  Tissue plasminogen activator inhibits NMDA-receptor-mediated increases in calcium levels in cultured hippocampal neurons.

Authors:  Samuel D Robinson; Tet Woo Lee; David L Christie; Nigel P Birch
Journal:  Front Cell Neurosci       Date:  2015-10-09       Impact factor: 5.505

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.